Bipolar Disorder
📧 Sign up to get email alerts when something new happens for Bipolar Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-04-20Clinical Trial Update: A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode [Phase 2]
Phase 2 study evaluating SAGE-217 in participants with Bipolar I/II disorder currently experiencing a major depressive episode has completed…
-
CLINICAL_TRIALS trial_result · 2022-04-19Clinical Trial Update: Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness [NA]
Clinical trial investigating integrated smoking cessation treatment for individuals with serious mental illness completed with results poste…
-
CLINICAL_TRIALS trial_result · 2022-04-18Clinical Trial Update: Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation [Phase 4]
Phase 4 clinical trial evaluating quetiapine for youth with substance use disorders and severe mood dysregulation has completed with posted …
-
FDA approval · 2022-04-05FDA Approved: IGALMI — Original Application (BioXcel Therapeutics, Inc.)
FDA approves IGALMI (dexmedetomidine) by BioXcel Therapeutics for the acute treatment of agitation in adults with schizophrenia or bipolar I…
-
CLINICAL_TRIALS trial_result · 2022-03-31Clinical Trial Update: ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness [Phase 4]
A Phase 4 trial update on Abilify (aripiprazole) for long-term effectiveness in bipolar disorder has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-03-31FDA Approved: CARBAMAZEPINE ER — Original Application (Bostal LLC)
FDA approved Bostal LLC's original-application generic extended-release carbamazepine (CARBAMAZEPINE ER), marking the first approval of this…
-
CLINICAL_TRIALS research · 2022-03-15Clinical Trial Update: The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression. [Phase 4]
A Phase 4 single-arm biomarker development trial evaluating ketamine for non-psychotic unipolar major depression and bipolar depression has …
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: LFMS: Initial Trial in Geriatric Bipolar Depression [NA]
An early-phase clinical trial update for LFMS in geriatric bipolar depression has been terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2022-02-17Clinical Trial Update: CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL) [Phase 4]
Phase 4 trial evaluating CAE Plus long-acting injectable in individuals with bipolar disorder at risk for treatment non-adherence; results p…
-
FDA approval · 2022-01-28FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Geodon (ziprasidone) submitted by Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2022-01-25Clinical Trial Update: Effect of Regulated Add -on Sodium Chloride Intake on Stabilization of Serum Lithium Concentration in Bipolar Disorder [Phase 4]
Phase 4 trial evaluating whether regulated add-on sodium chloride intake stabilizes serum lithium concentration in bipolar disorder.
-
CLINICAL_TRIALS trial_result · 2022-01-20Clinical Trial Update: Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression [Phase 3]
Phase 3 trial evaluating adjunctive celecoxib for bipolar postpartum depression was terminated.
-
FDA approval · 2022-01-13FDA Approved: LURASIDONE HYDROCHLORIDE — Supplemental Application (Accord Healthcare, Inc.)
FDA approved a supplemental application for lurasidone hydrochloride submitted by Accord Healthcare, Inc.
-
CLINICAL_TRIALS trial_result · 2022-01-03Clinical Trial Update: Modeling Mood Course to Detect Markers for Effective Adaptive Interventions- Aim 3 [Phase 1]
Phase 1 clinical trial update focused on modeling mood course to detect markers for effective adaptive interventions in bipolar disorder wit…
-
FDA approval · 2021-12-08FDA Approved: LAMOTRIGINE — Original Application (Yiling Pharmaceutical, Inc.)
The FDA approved Yiling Pharmaceutical's generic lamotrigine extended-release via Original Application (ANDA), enabling a generic lamotrigin…
-
FDA approval · 2021-12-01FDA Approved: CARBATROL — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for CARBATROL (carbamazepine) from Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2021-11-29FDA Approved: CHLORPROMAZINE HYDROCHLORIDE — Original Application (Chartwell RX, LLC)
FDA approved chlorpromazine hydrochloride from Chartwell RX, LLC under an original ANDA for generic use.
-
FDA approval · 2021-11-24FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved Teva's supplemental application for a generic olanzapine and fluoxetine fixed-dose combination product. This approval corre…
-
FDA approval · 2021-11-24FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved Teva's supplemental application for the olanzapine and fluoxetine combination product, expanding the regulatory status for …
-
FDA approval · 2021-11-19FDA Approved: OLANZAPINE — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for Olanzapine from Macleods Pharmaceuticals Limited.
-
FDA approval · 2021-11-18FDA Approved: OLANZAPINE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for a generic olanzapine product from Upsher-Smith Laboratories, LLC (ANDA204319).
-
FDA approval · 2021-11-12FDA Approved: QUETIAPINE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for a generic quetiapine product (ANDA204203). This marks a supplemental ap…
-
FDA approval · 2021-11-09FDA Approved: LAMOTRIGINE EXTENDED RELEASE — Supplemental Application (Par Health USA, LLC)
The FDA approved a supplemental application for Lamotrigine Extended Release from Par Health USA, LLC, approving a generic extended-release …
-
FDA approval · 2021-11-09FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for quetiapine fumarate from Macleods Pharmaceuticals Limited, enabling a generic version of the…
-
FDA approval · 2021-11-09FDA Approved: LAMOTRIGINE — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for lamotrigine (NorthStar Rx LLC) under an ANDA.